Incyte Genomics Inc (INCY)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Incyte Genomics Inc (INCY)
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Key Insights
Critical company metrics and information
Share Price
$75.92Market Cap
$14.63 BillionTotal Outstanding Shares
192.65 Million SharesTotal Employees
2,524Dividend
No dividendIPO Date
November 3, 1993SIC Description
Services-commercial Physical & Biological ResearchHomepage
https://www.incyte.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow | $-1.92 Billion |
Net Cash Flow, Continuing | $-1.92 Billion |
Net Cash Flow From Financing Activities, Continuing | $-2.04 Billion |
Exchange Gains/Losses | $-7.84 Million |
Net Cash Flow From Investing Activities | $24.48 Million |
Net Cash Flow From Operating Activities, Continuing | $101.85 Million |
Net Cash Flow From Investing Activities, Continuing | $24.48 Million |
Net Cash Flow From Financing Activities | $-2.04 Billion |
Net Cash Flow From Operating Activities | $101.85 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Net Income/Loss Attributable To Parent | $32.48 Million |
Net Income/Loss Available To Common Stockholders, Basic | $32.48 Million |
Research and Development | $2.59 Billion |
Basic Average Shares | $414.16 Million |
Income/Loss From Continuing Operations After Tax | $32.48 Million |
Costs And Expenses | $4.13 Billion |
Benefits Costs and Expenses | $3.80 Billion |
Gross Profit | $3.78 Billion |
Income Tax Expense/Benefit | $241.38 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Other Operating Expenses | $40.78 Million |
Net Income/Loss | $32.48 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Diluted Earnings Per Share | $0.19 |
Cost Of Revenue | $293.33 Million |
Income/Loss From Continuing Operations Before Tax | $273.86 Million |
Selling, General, and Administrative Expenses | $1.21 Billion |
Revenues | $4.08 Billion |
Diluted Average Shares | $417.34 Million |
Basic Earnings Per Share | $0.21 |
Operating Income/Loss | $-52.88 Million |
Operating Expenses | $3.84 Billion |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Fixed Assets | $773.10 Million |
Equity Attributable To Parent | $3.17 Billion |
Other Current Assets | $2.74 Billion |
Accounts Payable | $178.71 Million |
Liabilities And Equity | $5.01 Billion |
Noncurrent Liabilities | $339.56 Million |
Current Liabilities | $1.50 Billion |
Liabilities | $1.84 Billion |
Noncurrent Assets | $2.20 Billion |
Wages | $150.72 Million |
Assets | $5.01 Billion |
Inventory | $70.44 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Current Assets | $2.81 Billion |
Equity | $3.17 Billion |
Other Non-current Assets | $1.43 Billion |
Other Current Liabilities | $1.17 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.